Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study) Protocol: H8A-MC-LZAZ/ADC-040-A4

M
Martin Farlow, MD

Primary Investigator

Overview

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid.

Description

This study will test the hypothesis that solaneuzumab, administered as an intravenous infusion at a dose of 400 mg every 4 weeks for 156 weeks, will slow the decline in cognitive decline as compared with placebo in subjects with preclinical Alzheimer?s disease (AD).

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's Disease
  • Age: Between 65 Years - 85 Years
  • Gender: All

Inclusion Criteria
Normal thinking and memory function
Evidence of amyloid plaque build up in the brain
Has a study partner that is willing to participate as a source of information and has at least weekly contact with the subject
Exclusion Criteria
Receiving a prescription acetylcholinesterase inhibitor and/or memantine at screening or baseline
Diagnosed with another serious medical condition
Diagnosed with HIV
Diagnosed with schizophrenia
Resides in a skilled nursing facility
Pregnant, lactating, or child bearing potential


Additional Information:

Updated on 20 Nov 2022. Study ID: 1311691833

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center